Experimental immune cell therapy targets Hard-to-Treat cancers
NCT ID NCT05430360
First seen Apr 29, 2026 · Last updated May 14, 2026 · Updated 3 times
Summary
This early-phase study tested a personalized therapy called GT201 for people with advanced solid tumors that have spread or come back. The treatment uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are grown in a lab and given back along with chemotherapy and interleukin-2. The main goal was to check safety, with only 2 participants enrolled before the study was stopped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Hospital of Zhejiang University
Hangzhou, Zhejiang, China
Conditions
Explore the condition pages connected to this study.